GlassScriptPhysician profile
Jennifer H Shuemaker
NPI 1174784466
$3,179.55
in general payments reported to CMS, 2019-2025
29 companies · $533 in 2025
The $533 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $172 · 2021: $316 · 2022: $626 · 2023: $460 · 2024: $536 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,436 · Education: $92.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,436.24 |
| Education | $92.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $412.30 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $363.41 | 2019-2025 | Tavneos |
| Otsuka America Pharmaceutical, INC. | $312.64 | 2019-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $236.28 | 2019-2025 | Veltassa, Korsuva |
| Aurinia Pharma U.S., INC. | $219.92 | 2022-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $177.21 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $171.90 | 2019-2023 | Ultomiris |
| Calliditas Therapeutics US INC. | $154.54 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $129.55 | 2019-2025 | Vafseo |
| Travere Therapeutics, INC. | $115.85 | 2023-2025 | Filspari |
| Fresenius USA Marketing, INC. | $109.25 | 2019-2025 | Velphoro |
| Opko Pharmaceuticals, LLC | $104.54 | 2021-2023 | Rayaldee |
| Genzyme Corporation | $88.17 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $83.24 | 2019-2025 | |
| Nxstage Medical, INC. | $68.96 | 2019-2025 | Nxstage System One, Liberty Select Cycler |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $64.67 | 2024-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $60.35 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.90 | 2024-2025 | Jardiance |
| Shire North American Group INC | $33.89 | 2019 | |
| Daiichi Sankyo INC. | $31.50 | 2019 | |
| Allergan, INC. | $29.74 | 2019 | |
| Mallinckrodt Enterprises LLC | $27.72 | 2019 | |
| Apellis Pharmaceuticals, INC. | $26.38 | 2025 | Empaveli |
| Ultragenyx Pharmaceutical INC. | $20.90 | 2023 | |
| Pharmacosmos Therapeutics INC. | $20.01 | 2021 | |
| Novo Nordisk INC | $19.31 | 2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $17.29 | 2023 | Jardiance |
| Terumo Medical Corporation | $16.28 | 2020 | |
| Glaxosmithkline, LLC. | $11.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Shuemaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.